Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 18/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 16/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 14/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 14/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 14/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4680213 | 0.99 | MAPK1 (0.98) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL4345989 | 0.92 | MAPK1 (0.86) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL4679917 | 0.91 | MAPK1 (0.84) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL16404559 | 0.90 | MAPK1 (0.82) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12979744 | 0.90 | MAPK1 (0.82) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL4683081 | 0.90 | MAPK1 (0.82) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL4680167 | 0.88 | MAPK1 (0.78) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL4680529 | 0.88 | MAPK1 (0.78) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL16673928 | 0.88 | MAPK1 (0.78) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL16693528 | 0.88 | MAPK1 (0.78) | MAPK1PIK3CAMAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636228-B1 | NOVEL PYRIDOPYRAZINES AND USE THEREOF AS KINASE MODULATORS | AETERNA ZENTARIS GMBH (DE) | 2008-10-22 | — | — | EP | claimed |
| US-20070275972-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2007-11-29 | — | — | US | claimed |
| US-7276507-B2 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2007-10-02 | — | — | US | claimed |
| US-20040266777-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2004-12-30 | — | — | US | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260049111-A1 | METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER | MULTIVIR INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250382583-A1 | ENHANCED METHODS FOR INDUCING AND MAINTAINING NAIVE HUMAN PLURIPOTENT STEM CELLS | WASHINGTON UNIVERSITY ST LOUIS (US) | 2025-12-18 | — | — | US | disclosed |
| US-12454561-B2 | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer | MULTIVIR INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-12371667-B2 | Enhanced methods for inducing and maintaining naive human pluripotent stem cells | WASHINGTON UNIVERSITY (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250195516-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250172563-A1 | MATERIALS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-05-29 | — | — | US | disclosed |
| EP-3768698-B1 | METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER | MULTIVIR INC (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2014141165-A1 | USE OF INSULIN SIGNALING ANTAGONISTS, OPTIONALLY IN COMBINATION OF TRANSFECTION OF NON-BETA CELLS, FOR INDUCING INSULIN PRODUCTION | UNIVERSITE DE GENEVE (CH) | 2014-09-18 | — | — | WO | disclosed |
| US-8193186-B2 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2012-06-05 | — | — | US | disclosed |
| US-20070275972-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2007-11-29 | — | — | US | disclosed |
| US-7276507-B2 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ZENTARIS GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ZENTARIS GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ZENTARIS GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| US-20040266777-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275972-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | MKI67, MAP4K2, MAP3K5 | MAPK1 29/4885PIK3CA 207/4885MAPK8 134/4885 |
| US-20040266777-A1 | Pyridopyrazines and the use thereof as kinase inhibitors | PDXK, MKI67, MAP4K2 | MAPK1 17/4885PIK3CA 209/4885MAPK8 194/4885 |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | PLPBP, PDXK, MAP4K2 | MAPK1 58/4885PIK3CA 866/4885MAPK8 116/4885 |
| US-20250195516-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | MAPK1 97/4885PIK3CA 80/4885MAPK8 45/4885 |
| US-20260049111-A1 | METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER | TP53, HAVCR2, PDCD1LG2 | MAPK1 3953/4885PIK3CA 3199/4885MAPK8 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.